Frank Vinluan

@frankvinluan

Business journalist in Research Triangle Park on 's biotech team covering pharma, medtech, agtech. 71% free throw shooter. Genesis: Album 9, track 11.

North Carolina
Vrijeme pridruživanja: studeni 2010.

Tweetovi

Blokirali ste korisnika/cu @frankvinluan

Jeste li sigurni da želite vidjeti te tweetove? Time nećete deblokirati korisnika/cu @frankvinluan

  1. prije 1 sat

    ICYMI, won FDA approval Friday for , a peanut allergy therapy. The FDA decision covers kids 4-17 yrs.old...

    Poništi
  2. 1. velj

    carries an $890 a month wholesale price before any rebates or discounts. But says it will offer payment assistant programs that could reduce the cost to as low as $20 a month. The new drug is expected to launch in coming weeks.

    Prikaži ovu nit
    Poništi
  3. 1. velj

    The is not a cure. It's meant to reduce sensitivity so that a reaction to accidental peanut exposure is less severe. But comes with a warning that it can cause side effects, including anaphylaxis.

    Prikaži ovu nit
    Poništi
  4. 1. velj

    First FDA approval for a therapy goes to . The decision for covers kids 4-17 who have a confirmed peanut allergy diagnosis

    Prikaži ovu nit
    Poništi
  5. 31. sij

    When it comes to , size matters. Here's why thinks the smaller size of Cas14 gives it advantages for developing new drugs and diagnostics

    Poništi
  6. 30. sij

    Black Diamond Therapeutics sold more shares than initially planned, and topped its targeted price range, raising $201M from its . Proceeds will support a Phase 1-ready drug, as well as further development of its pipeline

    Poništi
  7. 29. sij

    This drug didn't pan out treating a rare blood disorder or chronic kidney disease. But with positive topline Phs 2 data in , some now see blockbuster potential. shares shot up 50% Tues.

    Poništi
  8. 28. sij

    RA Capital led the $50M Series A round for Quench Bio, a discovery-stage researching a new approach to treating inflammatory disorders

    Poništi
  9. 27. sij

    . is selling an experimental autoimmune drug to AstraZeneca, and a commercialized digestive drug to , to address antitrust concerns about its pending $63B merger w/

    Poništi
  10. 24. sij

    Epizyme’s drug wins accelerated FDA approval, the first for the company and the first nod for a drug treating the rare soft-tissue cancer epithelioid sarcoma...

    Poništi
  11. 23. sij

    FDA rejection letters typically stay private. Correspondence between the agency and shed light on the thinking that led to the rejection and subsequent approval of Duchenne muscular dystrophy drug

    Poništi
  12. 22. sij

    This new Eli Lilly facility will be built in a part of that had been an R&D campus for GlaxoSmithKline and its predecessors for decades. GSK sold the site in 2017, but still leases a small portion.

    Poništi
  13. 21. sij

    ICYMI, Revolution Medicines filed for a $100M late last week. Lead drug is in Phase 1 testing under partnership with Sanofi...

    Poništi
  14. 18. sij

    Details about that deal and more are in Revolution Medicines' S-1 filing:

    Prikaži ovu nit
    Poništi
  15. 18. sij

    Revolution is the company that acquired Warp Drive Bio in 2018, biotech that was also developing RAS drugs.

    Prikaži ovu nit
    Poništi
  16. 18. sij

    It got its start in 2015, spinning out of VC firm . was not Revolution's initial target, but that focus developed as the University of Illinois technology that formed the basis of the led it to a way to drug RAS.

    Prikaži ovu nit
    Poništi
  17. 18. sij

    RAS has become a hot target for research, but these proteins are hard to hit with small molecule drugs. They don't have sites where small molecules can bind. says its proprietary tech creates "druggable pockets" that drugs can bind to.

    Prikaži ovu nit
    Poništi
  18. 18. sij

    Revolution Medicines has a lead drug in the clinic under a partnership with . Now it's aiming for a $100M to advance its pipeline of RAS drugs:

    Prikaži ovu nit
    Poništi
  19. 16. sij

    Less than 2 months after announcing a corporate restructuring, Neon Therapeutics has agreed to an acquisition by BioNTech for $67M in stock. The deal values at $2.18 per share. The drug developer priced its 2018 IPO at $16 per share.

    Poništi
  20. 15. sij

    Nektar won't do those tests and it's not waiting to see what the FDA says. Hours after the panel vote, the company announced it will withdraw its application and stop investment in the drug, . announcement here:

    Prikaži ovu nit
    Poništi

Čini se da učitavanje traje već neko vrijeme.

Twitter je možda preopterećen ili ima kratkotrajnih poteškoća u radu. Pokušajte ponovno ili potražite dodatne informacije u odjeljku Status Twittera.

    Možda bi vam se svidjelo i ovo:

    ·